Labcorp to Offer Risk-Scoring Test for People With Advanced Liver Fibrosis Due to NASH
26 Janeiro 2022 - 11:00AM
Business Wire
Enhanced Liver Fibrosis (ELF™) Test Gauges
Likelihood of Disease Progression; Expands Labcorp’s Testing
Options for Nonalcoholic Fatty Liver Disease
For the millions of people in the United States living with an
advanced form of chronic liver disease, simply understanding the
potential for future complications could help stave off severe
damage and even a transplant. Labcorp (NYSE: LH), a leading global
life sciences company, is making this possible by offering the
Enhanced Liver Fibrosis (ELF™) test. Developed by Siemens
Healthineers, the physician-ordered blood test helps assess the
risk of disease progression in individuals—opening the door for
improved outcomes. The test has been granted De Novo marketing
authorization by the U.S. Food and Drug Administration.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220126005573/en/
Photo courtesy of Labcorp
The ELF test provides a numeric score to people with advanced
liver fibrosis caused by nonalcoholic steatohepatitis (NASH), a
type of nonalcoholic fatty liver disease (NAFLD) often tied to
obesity and diabetes. That score is combined with additional
evaluations and test results to determine the likelihood of
late-stage liver scarring and other serious conditions.
“Because NASH is typically addressed through lifestyle shifts
such as weight loss and frequent exercise, knowing your risk of
more severe damage can help you make the right changes at the right
time,” said Dr. Marcia Eisenberg, chief scientific officer of
Labcorp Diagnostics. “The ELF test gives doctors and patients
important information that can factor into the assessment of
treatment options. Adding it to Labcorp’s robust suite of
NASH-focused tests furthers our commitment to fighting chronic
liver disease and to our overarching goal to improve health and
improve lives.”
NAFLD is the collective term for conditions involving excess fat
accumulation in the liver not caused by alcohol use. These range
from a condition called “fatty liver,” to the more serious
condition known as NASH. Through liver cell injury and inflammation
from fatty buildup, NASH-caused advanced fibrosis can increase
liver-related morbidity and mortality if left unchecked.
There is currently no standard treatment for NASH beyond
exercise and other lifestyle modifications. Oftentimes, people
living with NASH don’t know it, as symptoms can be difficult to
recognize. This creates a challenge for patients and providers, and
it has led many health experts to refer to the disease as a silent
epidemic. Recent estimates suggest approximately 20 million people
in the U.S. have NASH. The prevalence of the disease is expected to
increase in the next several years, resulting in a growing, unmet
medical need.
Proper and widely available diagnostic and prognostic testing is
required to identify NAFLD and NASH cases and high-risk patients,
help slow disease progression and create a brighter future for
those living with this potentially deadly condition. Labcorp has
devoted significant resources to developing its strong NASH testing
portfolio, which includes tests for assessing a patient’s liver
status such as NASH FibroSure®, NASH FibroSure® Plus and
NASHnext™.
Additionally, the company continues to harness its leading
diagnostic and drug development capabilities to improve the
public’s understanding of NASH, help advance new treatments and
promote broad access to clinical trials.
For more information on Labcorp’s efforts to combat NASH, visit
www.labcorp.com/nash. Additional information on the
physician-ordered ELF test can be found at
www.labcorp.com/nash-testing.
About Labcorp
Labcorp is a leading global life sciences company that provides
vital information to help doctors, hospitals, pharmaceutical
companies, researchers, and patients make clear and confident
decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and improve lives. With over 70,000
employees, we serve clients in more than 100 countries. Labcorp
(NYSE: LH) reported revenue of $14 billion in FY2020. Learn more
about us at www.Labcorp.com or follow us on LinkedIn and Twitter
@Labcorp.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220126005573/en/
Labcorp Contacts: Media: Michele Mazur — 336-436-8263
Media@Labcorp.com
Investors: Chas Cook — 336-436-5076 Investor@Labcorp.com
Laboratory Corporation o... (NYSE:LH)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Laboratory Corporation o... (NYSE:LH)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024